Literature DB >> 2400748

Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma.

P Sevelda1, U Denison, M Schemper, J Spona, N Vavra, H Salzer.   

Abstract

Levels of oestrogen receptor (ER) and progesterone receptor (PgR) in ovarian cancer tissue were examined with regard to their prognostic importance for survival in 179 patients with primary epithelial ovarian cancer stage III or IV in relation to: FIGO-stage, histological type, histological grade, age, ascites, and postoperative residual tumour. Hormone receptor content was determined with the DCC-method, receptor values higher than 9 fmol/mg protein were considered positive. Response to postoperative chemotherapy was significantly correlated with PgR content (80% responders in the group with PgR positive tumours and only 61% responders in the group with PgR negative tumours). A Cox proportional hazards regression model identified histological grade, residual tumour, age and PgR content as independent prognostic factors for survival in advanced epithelial ovarian carcinoma. PgR content had particularly significant prognostic relevance for patients with postoperative residual tumour mass less than or equal to 2 cm in diameter. Within this group of patients, those who are PgR positive have a 2-years survival probability of 83% compared with only 51% in the PgR-negative group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400748     DOI: 10.1111/j.1471-0528.1990.tb16243.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  5 in total

1.  Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.

Authors:  Luis Felipe Sallum; Luis Otavio Sarian; Liliana Lucci De Angelo Andrade; José Vassallo; Fernando Augusto Soares; Glauce Aparecida Pinto; Patrícia Andréia Ferreira; Sophie Derchain
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

2.  Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies.

Authors:  J Akahira; T Inoue; T Suzuki; K Ito; R Konno; S Sato; T Moriya; K Okamura; A Yajima; H Sasano
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

3.  Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival.

Authors:  Miriam Lenhard; Lennerová Tereza; Sabine Heublein; Nina Ditsch; Isabelle Himsl; Doris Mayr; Klaus Friese; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-11-24       Impact factor: 4.430

4.  Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

Authors:  G Scambia; P Benedetti-Panici; G Ferrandina; M Distefano; G Salerno; M E Romanini; A Fagotti; S Mancuso
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

5.  Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.

Authors:  J-I Akahira; M Aoki; T Suzuki; T Moriya; H Niikura; K Ito; S Inoue; K Okamura; H Sasano; N Yaegashi
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.